Comparison of various diagnostic methods in assessing platelet count in patients with immune thrombocytopenia by Witkowski, Michal et al.
  
ONLINE FIRST
This is a provisional PDF only. Copyedited and fully formatted version will be made available soon.
Comparison of various diagnostic methods in assessing
platelet count in patients with immune thrombocytopenia
Authors:  Michal Witkowski, Magdalena Witkowska, Marzena Tybura-Sawicka,
Agata Majchrzak, Tadeusz Robak, Piotr Smolewski
DOI: 10.5603/AHP.a2021.0030




This article has been peer reviewed and published immediately upon acceptance.
It is an open access article, which means that it can be downloaded, printed, and distributed freely,
provided the work is properly cited.
Powered by TCPDF (www.tcpdf.org)
1 
 
ORIGINAL RESEARCH ARTICLE 
 
Comparison of various diagnostic methods in assessing platelet count in patients 
with immune thrombocytopenia 
 
Michal Witkowski1*, Magdalena Witkowska2, Marzena Tybura-Sawicka3, Agata 
Majchrzak1, Tadeusz Robak4, Piotr Smolewski2 
1Department of Haematology, Copernicus Memorial Hospital, Lodz, Poland 
2Department of Experimental Haematology, Medical University of Lodz, Poland 
3Department of Haemostasis Disorders, Medical University of Lodz, Poland 
4Hematology Clinic, Medical University of Lodz, Poland 
 
 
*Address for correspondence: Michal Witkowski, Department of Hematology, 
Copernicus Memorial Hospital, Ciolkowskiego 2, 93–513 Lodz, Poland; phone: +48 42 




Introduction: Accurate platelet count (PLTC) in immune thrombocytopenia is 
important in order to make therapeutic decisions. The basic method of assessing PLTC 
is peripheral blood morphology with EDTA or with citrate. The older way of assessing 
PLTC is measurement under the microscope (FONIO), and the newer way is the 
fluorescent method. The purpose of this study was to compare PLTC methods, and find 
the most reliable. 
Material and methods: PLTC was assessed using five methods in adult patients with 
previously untreated ITP (EDTA, citrate, FONIO, fluorescent, and immunofluorescent 
methods). 
Results: 66 patients were enrolled in the study. The median age was 56 and 56% were 
men. Median PLTC in EDTA was 69 G/L, in citrate 69 G/L, in fluorescence 69 G/L, in 
FONIO 90 G/L, and in immunofluorescence 83 G/L. A significant difference in PLTC 
was observed in comparing EDTA to immunofluorescence (53% ±123%), followed by 
FONIO (51% ±91%). PLTC from immunofluorescence differed from the fluorescent 
method by 40% ±78%. 
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Conclusions: The most valuable method for obtaining PLTC is the immunofluorescent 
method. These findings are especially important in helping to make therapeutic 
decisions during a challenging time for accessing medical care like a pandemic. 






Immune thrombocytopenia (ITP) is an acquired disease characterized by isolated low 
platelet count (PLTC) and an increased risk of bleeding [1]. The pathophysiology 
underlying this disease is still not completely understood. So far, several disease 
mechanisms have been proposed, but the most plausible includes increased platelet 
destruction due to sensitization of platelets by autoantibodies. It has been observed that 
these autoantibodies are mainly IgG, usually connected with IgM, directed against 
glycoprotein (GP) complexes IIb/IIIa, GPIb/IX and GPIa/IIa [2]. 
ITP can be classified as ‘primary’ when occurring without any underlying 
disease or ‘secondary’ when associated with another disease such as connective tissue 
disorder, a viral infection, or certain drugs. According to the American Society of 
Hematology (ASH) guidelines, ITP is diagnosed by identifying PLTC less than 100 
×109/L in the absence of other causes or disorders [3]. 
Despite the evidence that the PLTC by itself has limitations as an effective 
marker of the need for treatment, it is still the most commonly applied parameter used 
in ITP patients. The clinical value have differences in PLTC especially, when amount is 
below 20–30 G/L because of the influence on therapeutic decisions like starting 
immunosuppressive treatment [4]. 
The basic method of assessing PLTC is peripheral blood morphology 
anticoagulated with ethylene diamine tetracetic acid (EDTA) or with citrate. The older 
version involves counting platelets under the microscope, while the newer is the 
fluorescent method. There is a need to identify better laboratory tests of bleeding risk, 
other than provided by PLTC, which fails to provide information on platelets 
aggregation and their function. The answer may be flow cytometry (FCM) with 
immunofluorescent method, which is now available only in highly specialized 
3 
 
centralized laboratories but in future could be an inpatient testing method that might 
provide additional guidance [5]. 
To date, there have been no publications comparing all five different PLTC 
methods. 
In our study, we evaluate and compare for the first time the five different 
methods of evaluating PLTC in ITP patients: peripheral blood morphology with EDTA 
and with citrate, counting platelets under the microscope, fluorescent and 
immunofluorescent methods. We believe this is an important study, especially in an 
extremely challenging pandemic. 
 
Material and methods 
 
This study involved a group of 66 patients with an ITP diagnosis according to the ASH 
2019 guidelines [3]. The inclusion criteria were: age 18+, previously untreated, and 
primary disease. All the included patients had not received any medical treatment for at 
least one month before sampling. The group was composed of 27 women and 39 men, 
mean age 56 years [standard deviation (SD) 19]. In all patients we evaluated PLTC with 
five different methods: EDTA and citrate in peripheral blood, manually under the 
microscope, and fluorescent and immunofluorescent methods. 
About 5 mL of blood was drawn from a vein in the patient’s inner elbow region. 
The freshly collected whole blood samples were divided into tubes with tripotassium 
salt of EDTA and trisodium citrate and counted for PLTC by an automatic hematology 
analyzer, Sysmex XN100 (Sysmex Corporation, Kobe, Japan). Precautions were taken 
to ensure there were no time lapses. After blood collection, it was analyzed within four 
hours. The calibration status of the Sysmex analyzer was initially checked by the 
manufacturer. Quality control samples and maintenance procedures were performed 
daily according to the manufacturer’s instructions. 
 
Microscope method 
PLTC was also evaluated by manual platelet counting under the microscope (FONIO) 
[8]. A direct smear was made by placing a drop of blood onto a microscope slide and 
spreading it into a thin layer. Slides were stained with Giemsa stain and reviewed for 





We also analyzed the new fluorescent method (FFC) for counting platelets on the 
Sysmex XN1000 analyzer. In platelet counting by the FFC, platelets are stained with a 
fluorescent oxazine dye that is specifically bound with nucleic acid‐rich platelet 
organelles, for example ribosomes or mitochondria. They are irradiated with a 
semiconductor laser beam, and then the forward scattered light and side fluorescence 
intensities of each platelet are plotted on a 2D scattergram to differentiate and count the 
platelets. FFC helps in specific differentiation of platelets from other blood cells and 
interfering particles such as red blood cell fragments. What’s more, the analyzed sample 
volume of the FFC channel is about five times larger than those of standard methods. It 
provides highly precise data even in situations when the PLTC is extremely low. 
 
Immunofluorescent method 
Coagulation sodium citrate samples were used to evaluate the platelet count by the 
immunofluorescent method. The staining and gating protocol followed that proposed by 
the London Laboratory Service Group [7, 8] (Figure 1). Whole blood was incubated 
with FITC-labeled monoclonal antibody CD41a and CD61 (Becton Dickinson, San 







Figure 1. Gates used for analysis of platelets identified as CD61+ population (A–B). 
Statistical formula for platelet count in immunofluorescent method with flow cytometer 




For the statistical analysis of data obtained, the range of the measured variable, mean, 
median and SD were calculated, using statistical software (STATISTICA v.7.0, Tulsa, 
OK, USA). Data was presented as a median or mean SD values. The differences 
between values were evaluated with non-parametric Mann-Whitney test. For assessment 
of correlations, the Spearman’s rank correlation coefficient or Chi-squared test were 




This study was approved by the local ethics committee, and all patients provided written 






We enrolled 66 patients with previously untreated ITP. The majority of patients were 
male (n =37, 56%), with median age at diagnosis of 56 years (±19). The median PLTC 
in the EDTA method was 69 G/L (1–164), with citrate 69 G/L (1–205), with 
fluorescence 69 G/L (2–164), with FONIO 90 G/L (1–250), and with 
immunofluorescence 83 G/L (5–283 SD ±65) (Figure 2). The characteristics of the 




Figure 2. Platelets counts determined using immunofluorescence (dark blue), FONIO 
(red), fluorescence (green), citrate (violet), and standard analyzer EDTA (blue) methods 
 
 
Table 1. Characteristics of study group 
Study group 
Number of patients n =66; male 56% 
Age 56 ±19 years 
Mean platelet level  
EDTA analyzer 69 (1–164) G/L 
Citrate analyzer 69 (1–205) G/L 
Fluorescent method 69 (2–164) G/L 
Microscope (FONIO) 90 (1–250) G/L 
Immunofluorescent method 83(5–283) G/L 
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Platelet parameters  
Platelet distribution width (PDW) [fl] 16 (9–25) 
Mean platelet volume (MPV) [fl] 12 (9–15) 
Platelet large cell ratio (P-LCR) [%] 41 (10–59) 
Immature platelet fraction (IPF) [%] 18 (3–42) 
Red blood cell (RBC) [million/µL] 5 (3–6) 
White blood cell (WBC) [thousand/µL] 7 (3–29) 
Mean fluorescence intensity (MFI) 25,504 (10,559–59,667) 
 
 
The standard method (PLTC in peripheral blood count with EDTA) was 
compared to the other available diagnostic methods including the FONIO, citrate 
morphology, fluorescent and immunofluorescent methods. The mean and median of the 
measurements from the immunofluorescent method (p =0.01) and FONIO method (p 
<0.01) were significantly higher than from the analyzer. The biggest difference in PLTC 
was observed in the results comparing the immunofluorescence (53% ±123%), followed 
by the FONIO (51% ±91%) (Figure 3). The mean and median of the measurements with 
FFC and citrate did not differ significantly from the measurement from the analyzer. No 
difference was observed in PLTC when comparing the standard method to the FFC (7% 
±43%) and the morphology with citrate (7% ±58%). The PLTC results obtained with 









Because of the possibility of platelets aggregation, the obtained results were 
correlated with standard morphological platelet parameters (PDW, MPV, P-LCR), the 
number of white and red blood cells, with the fraction of immature platelets, and with 
the mean fluorescence intensity (MFI). There were no statistical differences observed in 




Determining the exact PLTC is crucial in ITP patients because of the decision to start 
treatment. To date, the most commonly used method to assess and observe PLTC in ITP 
diagnosis has been morphology for EDTA. This is a quick and cheap method but has 
unfortunately important drawbacks. One of them is EDTA-dependent pseudo-
thrombocytopenia, a commonly known laboratory phenomenon. Its prevalence has been 
observed to vary between 0.1–2% among hospitalized patients and 15–17% in patients 
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with an ITP diagnosis [9, 10]. A possible reason for this phenomenon may be 
agglutinating antibodies that recognize cytoadhesive receptors on platelet GPllb/IIIa 
which as a result cause platelet clumping [11]. 
We should be very careful in interpreting PLTC in ITP patients obtained with 
conventional EDTA methods which have limitations in platelet measurements such as 
poor accuracy and precision in the low PLTC and interference by nonplatelet particles. 
The perfect method for ITP patients is still being sought. The best method of 
counting platelets in samples from ITP patients is still a matter of debate. Due to its high 
imprecision and laboriosness, the manual method has fallen out of favor and been 
replaced by immunological platelet counting using FCM. In a study by Gatt et al. [8], 
the PLTC was assessed by standard EDTA measurement and the immunofluorescent 
method. The results were similar to those observed in our study. The PLTC assessed by 
FCM were higher than those measured by the standard EDTA method (mean difference 
4 ×109/L, p = –0.0011). There was an excellent correlation between the counts 
determined by the EDTA and immunofluorescence (r =0.89, p <0.0001). In the work by 
Bowles et al. [12] in ITP patients, measurement of the platelet count by the standard 
EDTA method frequently underestimated the PLTC as defined by the 
immunofluorescent method. In a group of 35 enrolled patients, the mean PLTC by 
standard EDTA method was 44 ×109/L and by immunofluorescence was 56 ×109/L (p 
<0.001). Similar results were observed by Harrison et al. [13]. 
Both these studies support our finding that the consistent common discrepancy in 
EDTA method of evaluating ITP patients underestimates PLTC. 
The platelet is an interesting but difficult cell to study. Immunofluorescent 
method provides a rapid, accurate and reproducible test for PLTC, and might be adopted 
by laboratories with appropriate FCM experience. One of the reasons why 
immunofluorescence may be more accurate and extremely useful in ITP patients is 
detecting the immature (reticulated) platelets [14, 15]. These are not routinely assessed 
by hematology analyzers, but are crucial in the evaluation of the bone marrow response 
to thrombocytopenia. 
A great hope for the future is the newly developed XN‐Series automated 
hematology analyzer, equipped with a novel dedicated channel for platelet analysis, 
which is based on the FFC method. Tanaka et al. [16] observed that FFC gave higher 
correlation with immunofluorescent method compared to standard EDTA method for 
samples with a PLTC ≤50 ×109/L. The same results were noted by Sun et al. [17]. 
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PLTC counted with FFC channel were much more accurate than other diagnostic 
methods including standard EDTA, especially in thrombocytopenic patients. 
FFC may be a more precise and accurate method even in ITP patients. 
Unfortunately, this observation was not confirmed in our study. 
It has been observed that ITP patients differ in their tendency to bleed despite 
similarly low platelet counts. Moreover, it has been appreciated that, as with the 
inherited platelet disorders, hemostasis depends not only on platelet count, but also on 
platelet function. 
On the other hand, there are study results addressing the question of whether 
tests of platelet function may predict bleeding in ITP patients, as most tests of platelet 
function are affected by low PLTC [18, 19]. Nowadays, immunofluorescence has many 
applications in the diagnostic work-up of not only PLTC but also platelet function 
testing [20, 21]. Platelet analysis by FCM has been applied to the detection of platelet 
antigens, platelet surface-bound proteins, platelet activation, measurement of reticulated 
platelets, intracellular calcium studies, and the measurement of platelet microparticles in 
vivo and in vitro [22–27]. It has been used to evaluate platelet function in research 
studies, and therefore these assays require clinical validation before they can be used as 
the standard diagnostic tool in ITP patients. 
There were some limitations of our study that should be acknowledged. It was a 
small group of ITP patients who were enrolled. This was supposed to be an exploratory 
study in order to gather the information necessary to estimate for a larger follow-up 
study. We believe that it would be very important to perform an outcome study to 
prospectively evaluate the PLTC methods as well as bleeding and thrombosis 
examination in a further group of patients. Moreover, there should be cost and benefit 
analyses made before the possible introduction of newer ways of assessing PLTC in ITP 
patients. 
The second drawback of our study was that we did not investigate the correlation 
with clinical outcomes. but there were no life-threatening bleeding episodes in any 
patients in our study. 
In our study, similar to previous studies, the immunofluorescent method seems 
to be the most valuable PLTC method in ITP patients. Clinical applications of FCM 
analysis have been pursued in individual specialized medical centers so far. This 
technique has not found widespread practice in clinical laboratories, mostly due to 
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difficult standardization process of method and the inherent biovariability in comparing 
normal and abnormal platelets. 
Despite these hurdles, it seems certain that immunofluorescence in ITP patients 
will continue to evolve into more practical and robust procedures that may eventually 




Accurate PLTC is very important in ITP patients. According to our study, the most 
reflective test for PLTC is the immunofluorescent method. These findings are especially 
important during a difficult time in accessing medical care in order to make therapeutic 
decisions such as a pandemic. FCM has emerged as an important technology for the 
study of platelets. Unfortunately, this method is still expensive and labor-intensive, so 
should be reserved for selected patients and situations. It also highlights the need to 
identify novel ways of assessing PLTC in various types of thrombocytopenia. 
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